NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
Clinical Trials
10,384 trialsNCT02601313 2026-03-18
ZUMA-2
Gilead Sciences
Phase 2 Completed
NCT03793361 2026-03-18
EREMISS
Centre Oscar Lambret
Phase 2 Completed
NCT04251949 2026-03-18
MuciLight
Centre Oscar Lambret
Phase 2 Completed
NCT04814108 2026-03-18
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Phase 2 Completed
NCT05359861 2026-03-18
Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Completed
NCT05962606 2026-03-18
Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.
Aptarion Biotech AG
Phase 2 Completed
NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02467270 2026-03-17
OPTIC
Takeda
Phase 2 Completed
NCT02818920 2026-03-17
TOP 1501
Duke University
Phase 2 Completed
NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT03462342 2026-03-17
CAPRI
University of Pennsylvania
Phase 2 Completed
NCT04484142 2026-03-17
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo
Phase 2 Completed
NCT00417495 2026-03-16
IGASSU
Centre Oscar Lambret
Phase 2 Completed
NCT00420563 2026-03-16
PAL-ANGI
Centre Oscar Lambret
Phase 2 Completed
NCT01303094 2026-03-16
T-DIS
Centre Oscar Lambret
Phase 2 Completed
NCT01658462 2026-03-16
VAROCE
Centre Oscar Lambret
Phase 2 Completed
NCT02437656 2026-03-16
METCAP
Centre Oscar Lambret
Phase 2 Completed
NCT02439034 2026-03-16
KETOCOL
Centre Oscar Lambret
Phase 2 Completed
NCT03643510 2026-03-16
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04609566 2026-03-16
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
Phase 2 Completed
NCT04703686 2026-03-16
Treatment by a Bispecific CD3xCD20 Antibody for Relapse/Refractory Lymphomas After CAR T-cells Therapy
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT05340413 2026-03-16
RADIOLA
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT01165346 2026-03-13
CKNO-HEP
Centre Oscar Lambret
Phase 2 Completed
NCT01303497 2026-03-13
ANGIO-TAX+
Centre Oscar Lambret
Phase 2 Completed
NCT01596816 2026-03-13
CKNO-PRO
Centre Oscar Lambret
Phase 2 Completed
NCT01900743 2026-03-13
REGO-SARC
Centre Oscar Lambret
Phase 2 Completed
NCT02648282 2026-03-13
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03475186 2026-03-13
Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Wake Forest University Health Sciences
Phase 2 Completed
NCT03945773 2026-03-13
CaboPoint
Ipsen
Phase 2 Completed
NCT04301778 2026-03-13
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04300647 2026-03-12
SKYSCRAPER-04
Hoffmann-La Roche
Phase 2 Completed
NCT07466758 2026-03-12
Personalized Pharmaconutrition Therapy for Myosteatosis, Sarcopenia, and Prognosis in Gastric Cancer Patients
Biruni University
Phase 2 Completed
NCT02723994 2026-03-11
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Incyte Corporation
Phase 2 Completed
NCT02829918 2026-03-11
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT03313804 2026-03-11
Priming Immunotherapy in Advanced Disease With Radiation
University of Kentucky
Phase 2 Completed
NCT04044937 2026-03-11
UC-GlioFET
University of California, San Francisco
Phase 2 Completed
NCT04301089 2026-03-11
Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT05526248 2026-03-11
ARAMON
Bayer
Phase 2 Completed
NCT00939627 2026-03-10
Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab
National Cancer Institute (NCI)
Phase 2 Completed
NCT02867956 2026-03-10
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
Sun Yat-sen University
Phase 2 Completed
NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT03446157 2026-03-10
Palbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03458260 2026-03-10
Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT03523702 2026-03-10
SPRINT
Albert Einstein College of Medicine
Phase 2 Completed
NCT04341883 2026-03-10
Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer
Sun Yat-sen University
Phase 2 Completed
NCT07460596 2026-03-10
Concentrated Complex Plant Dietary Elements for Chemotherapy-Induced Diarrhea
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT02153957 2026-03-09
Trial Evaluating an Enhanced Physical Activity Intervention to Improve Cognitive Late Effects in Children Treated With Cranial Radiation for Brain Tumors
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02257853 2026-03-09
Effectiveness of a Stress Reduction Intervention in Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03477539 2026-03-09
Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Mayo Clinic
Phase 2 Completed